Modern treatment strategies have resulted in an excellent overall
survival in the majority of patients with Hodgkin’s lymphoma.
PET-stratification is used to guide treatment in patients with limited
disease in clinical trials, but recent results indicate that combined
treatment with chemotherapy and radiotherapy is still the standard of
Recent clinical data presented at the annual meeting of the American
Society of Hematology underline the importance of incorporating
cytarabine in the induction treatment of younger patients with mantle
cell lymphoma, while other trials confirmed the importance of
immuno-chemotherapy with rituximab and bendamustine, especially in
Clonal evolutionary models of myeloma progression were the main focus
with respect to basic science highlights at ASH 2012. The
well-documented evidence for the existence of a
“Darwinian-branching” evolution pattern has major clinical
implications for the development of new treatment strategies and
The 54th annual meeting of the American Society of Hematology (ASH)
held in Atlanta, Georgia, 8th–11th December 2012, was attended by
21,000 participants from over 110 countries. Selecting the most
relevant data out of a wealth of > 5,000 abstracts and > 3,000
presentations represents a major challenge.
This short and personal overview summarizes new data in the field of
myeloproliferative neoplasms from the 2012 American Society of
Hematology meeting. In Polycythemia vera (PV) an hematocrit strictly
kept below 45 % was shown to be associated with a lower
cardiovascular event rate.
Hematopoietic stem cell transplantation (HSCT) is a developing
treatment modality, continuously being adapted to disease-specific
requirements, and, even more successfully, to the tolerability in a
growing target population.